Cited by 860Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentBone health and treatments

The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Open access

Eisenberger, Mario A., Blumenstein, Brent A., Crawford, E. David, Miller, Gary, McLeod, David G., Loehrer, Patrick J., Wilding, George, Sears, Kathy, Culkin, Daniel J., Thompson, Ian M., Bueschen, Anton J., Lowe, Bruce A.·1998·New England Journal of Medicine

DOI 10.1056/nejm199810083391504

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Combined androgen blockade for the treatment of metastatic prostate cancer consists of an antiandrogen drug plus castration. In a previous trial, we found that adding the antiandrogen flutamide to leuprolide acetate (a synthetic gonadotropin-releasing hormone that results in medical ablation of testicular function) significantly improved survival as compared with that achieved with placebo plus leuprolide acetate. In the current trial, we compared flutamide plus bilateral orchiectomy with placebo plus orchiectomy. METHODS: We randomly assigned patients who had never received antiandrogen therapy and who had distant metastases from adenocarcinoma of the prostate to treatment with bilateral orchiectomy and either flutamide or placebo. Patients were stratified according to the extent of disease and according to performance status. RESULTS: Of the 1387 patients who were enrolled in the trial, 700 were randomly assigned to the flutamide group and 687 to the placebo group. Overall, the incidence of toxic effects was minimal; the only notable differences between the groups were the greater rates of diarrhea and anemia with flutamide. There was no significant difference between the two groups in overall survival (P=0.14). The estimated risk of death (hazard ratio) for flutamide as compared with placebo was 0.91 (90 percent confidence interval, 0.81 to 1.01). Flutamide was not associated with enhanced benefit in patients with minimal disease. CONCLUSIONS: The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful improvement in survival among patients with metastatic prostate cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199810083391504

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate
Huggins, C., & Hodges, C. V. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,856
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Cancer statistics, 1997
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,000
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Self-citation
Leuprolide versus Diethylstilbestrol for Metastatic Prostate Cancer
The Leuprolide Study Group (1984) · New England Journal of Medicine · doi:10.1056/nejm198411153112004 · Cited by 622
The veterans administration cooperative urological research group's studies of cancer of the prostate
Byar, D. P. (1973) · Cancer · doi:10.1002/1097-0142(197311)32:5 · Cited by 595
Designs for group sequential tests
Fleming, T. R., Harrington, D. P., & O’Brien, P. C. (1984) · Controlled Clinical Trials · doi:10.1016/s0197-2456(84)80014-8 · Cited by 354
Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients
Prostate Cancer Trialists' Collaborative Group (1995) · The Lancet · doi:10.1016/s0140-6736(95)92163-x · Cited by 320
Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation
Rubinstein, L., Gail, M. H., & Santner, T. J. (1981) · Journal of Chronic Diseases · doi:10.1016/0021-9681(81)90007-2 · Cited by 270

Show all 25 references

Research works printed but not linked: 3

Huggins C, 1941, Cancer Res, 1, 293
10.1002/1097-0142(19931215)72:12+<3834::AID-CNCR2820721714>3.0.CO;2-Z · DOI
Eisenberger MA, 1994, Semin Oncol, 21, 613

Sorted by citations

Items 401–500 of 860

RADIATION THERAPY FOR THE TREATMENT OF LOCALLY ADVANCED AND METASTATIC PROSTATE CANCER
Thurman, S. A., Ramakrishna, N. R., & DeWeese, T. L. (2001) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70224-0 · Cited by 19
Direct Gastrointestinal Toxicity of Flutamide: Comparison of Irradiated and Nonirradiated Cases
Langenstroer, P., PORTER, H. J., McLeod, D. G., & Thrasher, J. B. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000106835.60202.81 · Cited by 19
Self-citation
Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
Sarosdy, M. F., Schellhammer, P. F., Johnson, R. T., Carroll, K., & Kolvenbag, G. J. C. M. (2000) · Urology · doi:10.1016/s0090-4295(99)00574-9 · Cited by 19
Angiotensin-converting enzyme inhibitors and the risk of cancer
Friis, S., Sørensen, H. T., Mellemkjøer, L., McLaughlin, J. K., Nielsen, G. L., Blot, W. J., & Olsen, J. H. (2001) · Cancer · doi:10.1002/1097-0142(20011101)92:9 · Cited by 156
Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy
Thomas, B., Smith, C., Evans, J., Button, M., Kumar, S., Palaniappan, N., Staffurth, J. N., Tanguay, J. S., & Lester, J. F. (2013) · Medical Oncology · doi:10.1007/s12032-013-0719-0 · Cited by 18
Agents That Target Androgen Synthesis in Castration-Resistant Prostate Cancer
Ferraldeschi, R., & Bono, J. S. D. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e31827e0b6f · Cited by 18
Evidence‐based Clinical Practice Guidelines for Prostate Cancer (Summary – JUA 2006 Edition)
Kamidono, S., Ohshima, S., Hirao, Y., Suzuki, K., Arai, Y., Fujimoto, H., Egawa, S., Akaza, H., Hara, I., Hinotsu, S., et al. (2008) · International Journal of Urology · doi:10.1111/j.1442-2042.2007.01959.x · Cited by 18
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study
Iguchi, T., Tamada, S., Kato, M., Yasuda, S., Otoshi, T., Hamada, K., Yamasaki, T., & Nakatani, T. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01413-1 · Cited by 18
Generalized Lymphadenopathy: A Rare Presentation of Disseminated Prostate Cancer
Oyan, B., Engin, H., & Yalçın, Ş. (2002) · Medical Oncology · doi:10.1385/mo:19:3:177 · Cited by 18
Golgi phosphoprotein 3 regulates metastasis of prostate cancer via matrix metalloproteinase 9.
Li, W., Qi, K., Wang, Z., Gu, M., Chen, G., Guo, F., & Wang, Z. (2015) · Europe PMC (PubMed Central) · Cited by 18
Impact of prior local therapy on overall survival in men with metastatic castration‐resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital
Patel, D. N., Jha, S., Howard, L. E., Amling, C. L., Aronson, W. J., Cooperberg, M. R., Kane, C. J., Terris, M. K., Chapin, B. F., & Freedland, S. J. (2018) · International Journal of Urology · doi:10.1111/iju.13806 · Cited by 18
Maximum androgen blockade: a clinical update.
Chodak, G. W. (2005) · Europe PMC (PubMed Central) · Cited by 18
Hormonal approaches in prostate cancer: Application in the contemporary prostate cancer patient
Beekman, K. W., & Hussain, M. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.11.003 · Cited by 18
Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?
Thomas, C., Baunacke, M., Erb, H. H. H., Fuessel, S., Erdmann, K., Putz, J., & Borkowetz, A. (2021) · Cancers · doi:10.3390/cancers14010008 · Cited by 18
N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review
Chen, Y., & Lan, T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1451957 · Cited by 18
Concept and viability of androgen annihilation for advanced prostate cancer
Mohler, J. L. (2014) · Cancer · doi:10.1002/cncr.28675 · Cited by 17
Efficacy, Patient-Reported Outcomes (PROs), and Tolerability of the Changing Therapeutic Landscape in Patients with Metastatic Prostate Cancer (MPC): A Systematic Literature Review
Seal, B. S., Asche, C. V., Puto, K., & Allen, P. D. (2013) · Value in Health · doi:10.1016/j.jval.2013.03.1628 · Cited by 17
Radium-223 for the treatment of prostate cancer
Hafeez, S., & Parker, C. C. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.761974 · Cited by 17
Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases
Zustovich, F., & Fabiani, F. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.01.003 · Cited by 17
Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary
Hofmann, M. R., Hussain, M., Dehm, S. M., Beltran, H., Wyatt, A. W., Halabi, S., Sweeney, C. J., Scher, H. I., Ryan, C. J., Feng, F. Y.-C., et al. (2020) · Urology · doi:10.1016/j.urology.2020.12.021 · Cited by 17
The Role of the FSH System in the Development and Progression of Prostate Cancer
Crawford, E. D., Rove, K. O., Schally, A. V., Rick, F. G., Block, N. L., Beveridge, T. J. R., Dahdal, D. N., & Marshall, D. C. (2014) · American Journal of Hematology / Oncology® · Cited by 17
Self-citation
Prostate cancer and the androgen receptor: Strategies for the development of novel therapeutics
Mendelsohn, L. G. (2000) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8385-6_6 · Cited by 17
A randomized study of docetaxel and dexamethasone with low‐ or high‐dose estramustine for patients with advanced hormone‐refractory prostate cancer
Nelius, T., Klatte, T., Yap, R., Kalinski, T., Röpke, A., Filleur, S., & Allhoff, E. P. (2006) · British Journal of Urology · doi:10.1111/j.1464-410x.2006.06324.x · Cited by 17
Combined Androgen Blockade: An Update
Klotz, L. H. (2006) · Urologic Clinics of North America · doi:10.1016/j.ucl.2005.12.001 · Cited by 17
Agents in development for prostate cancer prevention
Nelson, W. G. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.12.1541 · Cited by 17
Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer
Zheng, X., Zhao, X., Xu, H., Han, X., Xu, H., Dong, X., Peng, R., Yang, L., Wei, Q., & Ai, J. (2019) · Medicine · doi:10.1097/md.0000000000017748 · Cited by 16
Molecular Modeling, Docking and ADMET of Dimethylthiohydantoin Derivatives for Prostate Cancer Treatment
Lotfy, K. (2015) · Journal of Biophysical Chemistry · doi:10.4236/jbpc.2015.64010 · Cited by 15
Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer
Kohli, M., Oberg, A. L., Mahoney, D. W., Riska, S. M., Sherwood, R., Zhang, Y., Zenka, R. M., Sahasrabudhe, D. M., Qin, R., & Zhang, S. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.03.006 · Cited by 17
Roles of Interleukin-1 Receptor Antagonist in Prostate Cancer Progression
Fan, Y.-C., Lee, K., & Tsai, Y.-C. (2020) · Biomedicines · doi:10.3390/biomedicines8120602 · Cited by 16
Liver Microenvironment Response to Prostate Cancer Metastasis and Hormonal Therapy
Buxton, A. K., Abbasova, S., Bevan, C. L., & Leach, D. A. (2022) · Cancers · doi:10.3390/cancers14246189 · Cited by 17
Etude randomisée multicentrique comparant la castration médicale par triptoréline à la castration chirurgicale dans le traitement du cancer de la prostate localement avancé ou métastatique
Botto, H., Morgan Rouprêt, A., Mathieu, F., & Richard, F. (2007) · The French Journal of Urology · doi:10.1016/s1166-7087(07)92270-8 · Cited by 16
Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists
Kawakami, J., & Morales, Á. (2013) · Canadian Urological Association Journal · doi:10.5489/cuaj.540 · Cited by 16
Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
Agarwal, N., Sonpavde, G., & Sartor, O. A. (2010) · Future Oncology · doi:10.2217/fon.10.168 · Cited by 16
Development of a DNA biosensor based on MCM41 modified screen-printed graphite electrode for the study of the short sequence of the p53 tumor suppressor gene in hybridization and its interaction with the flutamide drug using hemin as the electrochemical label
Raoof, J. B., Bagheryan, Z., & Hashkavayi, A. B. (2020) · New Journal of Chemistry · doi:10.1039/c9nj04569d · Cited by 16
The changing pattern of management for hormone-refractory, metastatic prostate cancer
James, N. D., Bloomfield, D. J., & Luscombe, C. J. (2006) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500880 · Cited by 16
The Unreasonable Ineffectiveness of Fisherian “Tests” in Biology, and Especially in Medicine
McCLOSKEY, D. N., & Ziliak, S. T. (2009) · Biological Theory · doi:10.1162/biot.2009.4.1.44 · Cited by 15
Chemotherapy for metastatic castrate-sensitive prostate cancer
Miller, R. E., & Sweeney, C. J. (2016) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.10 · Cited by 15
Integrating the immune microenvironment of prostate cancer induced bone disease
Ihle, C. L., & Owens, P. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23192 · Cited by 15
Differentiating agents and the treatment of prostate cancer: vitamin D and peroxisome proliferator-activated receptor gamma ligands
LEIBOWITZ, S. F. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00352-x · Cited by 15
Serum Hemoglobin Levels Predict Response to Strontium-89 and Rhenium-186-HEDP Radionuclide Treatment for Painful Osseous Metastases in Prostate Cancer
van der Poel, H. G., Antonini, N. F., Hoefnagel, C. A., Horenblas, S., & Olmos, R. A. V. (2006) · Urologia Internationalis · doi:10.1159/000092935 · Cited by 15
Immune Response to Sipuleucel-T in Prostate Cancer
Thara, E., Dorff, T. B., Averia, M., Luther, M., Reed, M., Pinski, J., & Quinn, D. I. (2012) · Cancers · doi:10.3390/cancers4020420 · Cited by 15
Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed
Ornstein, D. K., Smith, D. S., & Andriole, G. L. (1998) · Urology · doi:10.1016/s0090-4295(98)00424-5 · Cited by 15
Systemic treatment and new developments in advanced prostate cancer
Sternberg, C. N. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)80016-2 · Cited by 15
Follow-up of conservatively managed prostate cancer
Messing, E. M., & Thompson, I. M. (2003) · Urologic Clinics of North America · doi:10.1016/s0094-0143(03)00050-8 · Cited by 15
Self-citation
Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer
Kohli, M., Qin, R., Jiménez, R. E., & Dehm, S. M. (2012) · Advances in Urology · doi:10.1155/2012/781459 · Cited by 14
Total Androgen Blockade Versus a Luteinizing Hormone–Releasing Hormone Agonist Alone in Men With High-Risk Prostate Cancer Treated With Radiotherapy
Nanda, A., Chen, M., Moran, B. J., Braccioforte, M. H., Dosoretz, D. E., Salenius, S. A., Katin, M. J., Ross, R., & D'Amico, A. V. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.03.034 · Cited by 14
Androgen-deprivation therapy alone versus combined with radiation therapy or chemotherapy for nonlocalized prostate cancer: a systematic review and meta-analysis
Wei, Q., Han, P., Lei, J., Liu, L.-R., Song, T., Yang, L., & Meng, Y. (2015) · Asian Journal of Andrology · doi:10.4103/1008-682x.150840 · Cited by 14
Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol
Clark, E., Morton, M., Sharma, S., Fisher, H., Howel, D., Walker, J., Wood, R., Hancock, H. C., Maier, R. H., Marshall, J., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-034708 · Cited by 13
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models)
Palicelli, A., Croci, S., Bisagni, A., Zanetti, E., de Biase, D., Melli, B., Sanguedolce, F., Ragazzi, M., Zanelli, M., Chaux, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212297 · Cited by 14
Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis
Naiki, T., Takahara, K., Ito, T., Nakane, K., Sugiyama, Y., Koie, T., Shiroki, R., Miyake, H., & Yasui, T. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02071-y · Cited by 14
Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry
van den Bergh, G. P. A., Kuppen, M. C. P., Westgeest, H. M., Mehra, N., Gerritsen, W. R., Aben, K. K. H., van Oort, I. M., van Moorselaar, R. J. A., Somford, D. M., van den Eertwegh, A. J. M., et al. (2022) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-022-00605-7 · Cited by 14
A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma
Lin, Y., Chen, C., Hou, C., Chang, P., & Tsui, K. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.236 · Cited by 14
Combined Androgen Blockade in Advanced Prostate Cancer: Looking Back to Move Forward
Chodak, G. W., Gomella, L. G., & Phung, D. (2007) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2007.n.019 · Cited by 14
Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL
Jiménez, J. A., Li, X., Zhang, Y., Bae, K.-H., Mohammadi, Y., Pandya, P. H., Kao, C. H., & Gardner, T. A. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.62 · Cited by 14
Structure–activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists
Yoshino, H., Sato, H., Tachibana, K., Shiraishi, T., Nakamura, M., Ohta, M., Ishikura, N., Nagamuta, M., Onuma, E., Nakagawa, T., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.03.036 · Cited by 14
Combined Androgen Blockade Revisited: Emerging Options for the Treatment of Castration-Resistant Prostate Cancer
Simmons, M. N., & Klein, E. A. (2009) · Urology · doi:10.1016/j.urology.2008.09.040 · Cited by 14
Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy
VanderWeele, D. J., Antonarakis, E. S., Carducci, M. A., Dreicer, R., Fizazi, K. S., Gillessen, S., Higano, C. S., Morgans, A. K., Petrylak, D. P., Sweeney, C. J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01595 · Cited by 14
Comparative clinical effects and cost–effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China
Liu, M., Qu, S., Liu, Y., Yao, X., & Jiang, W. (2019) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2018-0133 · Cited by 13
Prostate cancer
Каприн, А. Д., Алексеев, Б. Я., Matveev, V. B., Pushkar', D. I., Govorov, A. V., Gorban, N. A., Kirichek, A. A., Бирюков, В. А., Волкова, М. И., Гулидов, И. А., et al. (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2021.2.200959 · Cited by 15
Management of Metastatic Hormone-Sensitive Prostate Cancer
Bernard, B. D., & Sweeney, C. J. (2015) · Current Urology Reports · doi:10.1007/s11934-015-0488-8 · Cited by 13
Factors associated with the survival of prostate cancer patients with rectal involvement
Wang, H., Yao, Y., & Li, B. (2014) · Diagnostic Pathology · doi:10.1186/1746-1596-9-35 · Cited by 13
Oligometastatic Prostate Cancer Should Be Studied and Treated Differently to High-volume Disease. Con: The Underlying Biology is the Same, So They Should Not Be Treated Differently
James, N. D. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.01.018 · Cited by 13
Efficacy and Safety of Combined Androgen Blockade with Antiandrogen for Advanced Prostate Cancer
Yang, Y., Chen, R., Sun, T., Zhao, L., Liu, F., Ren, S., Wang, H., Lu, X., Gao, X., Xu, C., et al. (2019) · Current Oncology · doi:10.3747/co.26.4203 · Cited by 13
Markers of Iron Flux during Testosterone-Mediated Erythropoiesis in Older Men with Unexplained or Iron-Deficiency Anemia
Artz, A. S., Stephens‐Shields, A. J., Bhasin, S., Ellenberg, S. S., Cohen, H. J., & Snyder, P. J. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa521 · Cited by 14
Discovery of 7α-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure–activity relationships
Tachibana, K., Imaoka, I., Yoshino, H., Emura, T., Kodama, H., Furuta, Y., Kato, N., Nakamura, M., Ohta, M., Taniguchi, K., et al. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.09.072 · Cited by 13
Prostate cancer: management of advanced disease
Droz, J., Fléchon, A., & Terret, C. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf644 · Cited by 14
Prostate Cancer-Specific Survival and Clinical Progression-Free Survival in Men with Prostate Cancer Treated Intermittently with Testosterone Inactivating Pharmaceuticals
Scholz, M. C., Lam, R. Y., Strum, S. B., Jennrich, R. I., Johnson, H. J., & Trilling, T. (2007) · Urology · doi:10.1016/j.urology.2007.04.015 · Cited by 13
Hormonal treatment for prostate cancer
Harris, K. A., & Small, E. J. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.3.493 · Cited by 13
The evolution of hormonal therapy for prostatic carcinoma.
Brawer, M. K. (2001) · Europe PMC (PubMed Central) · Cited by 13
Approach to pulmonary metastases
Yoneda, K. Y., Louie, S., & Shelton, D. K. (2000) · Current Opinion in Pulmonary Medicine · doi:10.1097/00063198-200007000-00018 · Cited by 13
Treatments for Improving Survival of Patients with Prostate Cancer
David, A. K., Khwaja, R., & Hudes, G. R. (2003) · Drugs & Aging · doi:10.2165/00002512-200320090-00005 · Cited by 13
Controversies Surrounding Androgen Deprivation for Prostate Cancer
Patterson, S. G., Balducci, L., & Pow‐Sang, J. M. (2002) · Cancer Control · doi:10.1177/107327480200900406 · Cited by 13
Abiraterone acetate and prednisolone for metastatic castration‐resistant prostate cancer failing androgen deprivation and docetaxel‐based chemotherapy: A phase II bridging study in K orean and T aiwanese patients
Kwak, C. H., Wu, T. T., Lee, H. M., Wu, H. C., Hong, S. J., Ou, Y. C., Byun, S., Rhim, H. Y., Kheoh, T. S., Wan, Y., et al. (2014) · International Journal of Urology · doi:10.1111/iju.12589 · Cited by 12
Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life
Azim, H. A., & Mok, T. S. K. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282ff0f48 · Cited by 12
Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats
Gonçalves, B. F., Campos, S. G. P., Fávaro, W. J., Brandt, J. Z., Pinho, C. F., Justulin, L. A., Taboga, S. R., & Scarano, W. R. (2018) · Hormones and Cancer · doi:10.1007/s12672-018-0323-z · Cited by 12
Prostate Cancer
Nelson, W. G., Carter, H. B., DeWeese, T. L., Antonarakis, E. S., & Eisenberger, M. A. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00084-9 · Cited by 13
Self-citation
An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer
Roy, S., Zaorsky, N. G., Bagshaw, H. P., Berlín, A., Tree, A. C., Turner, S., Koontz, B. F., Nguyen, P. L., Chen, R. C., Dess, R. T., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.12.005 · Cited by 12
A patient-level data meta-analysis of standard-of-care treatments from eight prostate cancer clinical trials
Geifman, N., & Butte, A. J. (2016) · Scientific Data · doi:10.1038/sdata.2016.27 · Cited by 12
Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer–specific Mortality: Competition Between Age and Time to Biochemical Failure
Jackson, W., Suresh, K., Tumati, V., Dess, R. T., Soni, P., Zhao, S. G., Zumsteg, Z. S., Hannan, R., Hollenbeck, B. K., George, A. K., et al. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.04.014 · Cited by 12
Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis
Fiorica, F., Buttigliero, C., Grigolato, D., Muraro, M., Turco, F., Munoz, F. H., & Tucci, M. (2022) · Current Oncology · doi:10.3390/curroncol29120747 · Cited by 12
Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer: a single-arm prospective study using a historical control for comparison
Li, Y., Zhang, S.-F., Zhang, T.-T., Li, L., Gan, W., Jia, H., Xie, S., Ji, H.-H., & He, D. (2013) · Asian Journal of Andrology · doi:10.1038/aja.2013.89 · Cited by 12
MicroRNAs in androgen-dependent PCa
Sun, J. (2012) · Frontiers in bioscience · doi:10.2741/4137 · Cited by 12
Characterization of Prognostic Factors and Efficacy in a Phase-II Study with Docetaxel and Estramustine for Advanced Hormone Refractory Prostate Cancer
Nelius, T., Reiher, F., Lindenmeir, T., Klatte, T., Rau, O., Burandt, J., Filleur, S., & Allhoff, E. P. (2005) · Oncology Research and Treatment · doi:10.1159/000088297 · Cited by 12
The truth is out there: an overall perspective on androgen deprivation
Hellerstedt, B. A., & Pienta, K. J. (2003) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/s1078-1439(03)00046-2 · Cited by 12
Weekly Administration of Docetaxel in Patients with Hormone-refractory Prostate Cancer: a Pilot Study on Japanese Patients
Kojima, T. (2004) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyh021 · Cited by 12
Will the experience with tamoxifen in breast cancer help define the role of antiandrogens in prostate cancer?
Chodak, G. W., & Kolvenbag, G. J. C. M. (2001) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500518 · Cited by 12
Eligard®: Advantages for Optimal Testosterone Control
TOMBAL, B. F., & Berges, R. R. (2006) · European Urology Supplements · doi:10.1016/j.eursup.2006.08.007 · Cited by 12
Progress toward Identifying Aggressive Prostate Cancer
Eisenberger, M., & Partin, A. W. (2004) · New England Journal of Medicine · doi:10.1056/nejme048119 · Cited by 12
Self-citation
Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer
Freeman, M. N., Jang, A., Zhu, J., Sanati, F., Nandagopal, L., Ravindranathan, D., Desai, A., Phone, A., Nussenzveig, R. H., Jaeger, E., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab057 · Cited by 11
Disruption of CCL2 in Mesenchymal Stem Cells as an Anti-Tumor Approach against Prostate Cancer
Bui, Q. T., Lee, K., Fan, Y.-C., Lewis, B. S., Deng, L., & Tsai, Y. (2023) · Cancers · doi:10.3390/cancers15020441 · Cited by 11
Clinical characteristics and quality‐of‐life in patients surviving a decade of prostate cancer with bone metastases
Klaff, R., Berglund, A., Varenhorst, E., Hedlund, P. O., Jønler, M., Sandblom, G., & the Scandinavian Prostate Cancer Group (SPCG) Study No. 5 (2015) · British Journal of Urology · doi:10.1111/bju.13190 · Cited by 11
Clinical presentation and predictors of survival related to extent of bone metastasis in 900 prostate cancer patients
Klaff, R., Varenhorst, E., Berglund, A., Hedlund, P. O., Sjöberg, F., Sandblom, G., & The SPCG-5 Study Group (2016) · Scandinavian Journal of Urology · doi:10.1080/21681805.2016.1209689 · Cited by 11
Lack of Racial Survival Differences in Metastatic Prostate Cancer in National Cancer Data Base (NCDB): A Different Finding Compared to Non-metastatic Disease
Thomas, T. V., Gordy, X. Z., Lirette, S. T., Albert, A. A., Gordy, D. P., Vijayakumar, S., & Vijayakumar, V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.533070 · Cited by 11
Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis
Yanagisawa, T., Kimura, T., Hata, K., Narita, S., Hatakeyama, S., Mori, K., Sano, T., Otsuka, T., Iwamoto, Y., Enei, Y., et al. (2022) · World Journal of Urology · doi:10.1007/s00345-022-04030-2 · Cited by 11
Trends in Hormonal Management of Prostate Cancer:
Bondy, S. J., Iscoe, N., Rothwell, D. M., Gort, E. H., Fleshner, N. E., Paszat, L. F., & Browman, G. P. (2001) · Medical Care · doi:10.1097/00005650-200104000-00009 · Cited by 11
BENIGN AND MALIGNANT NEOPLASMS OF PROSTATE
Walsh, P. C. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67211-4 · Cited by 11
The Case for Diethylstilbestrol
Whitesel, J. A. (2003) · The Journal of Urology · doi:10.1016/s0022-5347(05)64099-2 · Cited by 11
Early versus delayed endocrine therapy for prostate cancer
Schröder, F. H. (2007) · Endocrine Related Cancer · doi:10.1677/erc-06-0022 · Cited by 11
Targeted therapies for prostate cancer
Asatiani, E., & Gelmann, E. P. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.2.283 · Cited by 11
Phase I Trial of Oral Estramustine and 3-hr Infusional Paclitaxel for the Treatment of Hormone Refractory Prostate Cancer
Kuzel, T. M., Kies, M. S., Wu, N., Hsieh, Y., & RADEMAKER, A. W. (2002) · Cancer Investigation · doi:10.1081/cnv-120002488 · Cited by 11

Authors: Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., Bueschen, A. J., & Lowe, B. A.
Affiliations: Johns Hopkins Hospital (US)
SWOG Cancer Research Network (US)
University of Colorado Denver (US)
Walter Reed National Military Medical Center (US)
University of Wisconsin–Madison (US)
University of Oklahoma Health Sciences Center (US)
University of Alabama at Birmingham (US)
Oregon Health & Science University (US)
ORCID: Eisenberger, Mario A.
Blumenstein, Brent A.
Crawford, E. David
McLeod, David G.
Loehrer, Patrick J.
Wilding, George
Culkin, Daniel J.
Thompson, Ian M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1998-10-08
Volume: 339
Issue: 15
Pages: 1036-1042
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199810083391504
OpenAlex: W2003985632
Cited by: 859
References: 25
Citations by year: 2026: 2 · 2025: 5 · 2024: 8 · 2023: 12 · 2022: 20 · 2021: 15 · 2020: 21 · 2019: 26 · 2018: 25 · 2017: 23 · 2016: 34 · 2015: 52 · 2014: 49 · 2013: 51 · 2012: 37
FWCI: 37.16
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (2u10ca038926-25)
National Cancer Institute (CA-32102, CA 42777, U10CA032102, U10CA042777, CA 38926)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords: metastatic prostate cancer, bilateral orchiectomy, flutamide, combined androgen blockade, leuprolide, antiandrogen therapy, overall survival, adverse effects, anemia, diarrhea
MeSH terms: Adenocarcinoma, Adult, Aged, Aged, 80 and over, Androgen Antagonists, Bone Neoplasms, Combined Modality Therapy, Double-Blind Method, Flutamide, Humans, Male, Middle Aged, Orchiectomy, Prostatic Neoplasms, Soft Tissue Neoplasms, Survival Analysis, Prostate-Specific Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks